重新审视洛莫司汀在胶质瘤治疗中的生物学与联合治疗前景
本文综述烷化剂替莫唑胺(TMZ)与洛莫司汀(CCNU)在恶性胶质瘤治疗中的作用,指出两者均不可避免出现耐药。CCNU虽临床有效但安全性不如TMZ,近期成人和儿童胶质瘤阳性试验重燃兴趣,但除MGMT外的耐药机制认识有限,需结合分子生物学与纵向分析优化临床应用和联合策略。
要点
- TMZ和CCNU是恶性胶质瘤最有效的全身药物,但所有患者终将耐药。
- CCNU临床有效,但安全性不如TMZ限制其使用。
- 近期成人和儿童胶质瘤阳性试验重燃对亚硝基脲类兴趣。
核心结论
- CCNU仍是恶性胶质瘤有效药物,但耐药机制认识不足,需优化临床应用并探索联合策略。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- TMZ和CCNU是恶性胶质瘤最有效的全身药物,但耐药不可避免导致肿瘤不可治愈。
- CCNU临床有效但安全性不如TMZ,使用相对受限。
- 近期成人和儿童胶质瘤阳性临床试验重燃对CCNU等亚硝基脲类兴趣。
- TMZ耐药与MGMT和错配修复通路状态相关,但亚硝基脲类除MGMT外的耐药机制认识有限。
临床怎么用
- 可重新审视CCNU在胶质瘤治疗中的定位,关注其与TMZ的安全性差异。
- 结合分子生物学和纵向样本分析,探索亚硝基脲类敏感性/耐药标志物以优化患者选择。
- 关注联合治疗策略以提高CCNU疗效。
局限性
- 摘要未报告综述的检索范围、纳入标准及证据等级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The alkylating agents temozolomide (TMZ) and lomustine (CCNU) are the most effective systemic agents for malignant gliomas. However, resistance-whether intrinsic or acquired-inevitably develops in all patients, and these tumors remain incurable. Although CCNU has demonstrated clinical benefit, its clinical use has been relatively limited due to a less favorable safety profile compared to TMZ. Recently, interest in CCNU and other nitrosoureas has been renewed in light of positive clinical trials in both adult and pediatric gliomas. Despite this renewed attention, critical questions remain unaddressed regarding the use of nitrosoureas. While resistance and response to temozolomide have been associated with the status of both MGMT and the mismatch repair DNA repair pathway, our understanding of the unique mechanisms of resistance to nitrosoureas beyond MGMT remains limited. Recent advances in molecular biology, preclinical models, and the use of longitudinal analyses of treated samples provide new insights, offering opportunities to refine clinical use and develop novel strategies. In this review, we explore the current role of nitrosoureas in glioma treatment, examine known and emerging mechanisms of sensitivity and resistance to these agents, and explore the potential for combination approaches to enhance their efficacy.
引用
- Bellamy C, Hajal C, Ligon KL, et al. Revisiting an old therapy for new, promising combinations: Biology and perspectives of lomustine in glioma treatment. Neuro Oncol. 2025. PMID: 40827019. doi:10.1093/neuonc/noaf192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。